Neptune Technologies Bioressources, Laval, Quebec, Canada, has formed an operating pharmaceutical subsidiary named Acasti Pharma Inc., which will carry out the research, development and commercialization of active pharmaceutical ingredients for cardiovascular disease. According to its business strategy, Acasti Pharma will pursue negotiations with the objective of entering strategic pharmaceutical alliances. Neptune has granted Acasti Pharma a license to rights of its intellectual property (IP) portfolio related to cardiovascular applications, allowing the group to develop novel active pharmaceutical ingredients into commercial products for three pharmaceutical markets, namely the over-the-counter (OTC), the medical food (MF) and the prescription drug (Rx) markets. Acasti Pharma is preparing an investigational new drug application for FDA and a clinical trial application with Health Canada. Acasti Pharma is working to advance a portfolio of proprietary novel omega 3 phospholipids through the pharmaceutical development pathway for prescription MF, OTC and Rx applications.